Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (755) Apply Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (17) Apply Summaries of opinion filter Orphan designations (133) Apply Orphan designations filter Referrals (16) Apply Referrals filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (418) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (62) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (4) Apply Initial authorisation filter Post-authorisation (9) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (19) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (172) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (2) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (39) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (24) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Exceptional circumstances Remove Exceptional circumstances filter Conditional approval (92) Apply Conditional approval filter Generic (346) Apply Generic filter Orphan medicine (320) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

765 results

Remove all filtersRemove all filters

Medicine type Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Tibsovo (updated)

Ivosidenib, Leukemia, Myeloid, Acute; Cholangiocarcinoma
Date of authorisation: 04/05/2023, , , Authorised, Last updated: 12/05/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 5, Authorised, Last updated: 12/05/2023
List item

Human medicine European public assessment report (EPAR): Lenvima (updated)

lenvatinib mesilate, Thyroid Neoplasms
Date of authorisation: 28/05/2015, , , Revision: 18, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Veklury (updated)

remdesivir, COVID-19 virus infection
Date of authorisation: 03/07/2020, , Revision: 18, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Kymriah (updated)

tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018, , Revision: 14, Authorised, Last updated: 10/05/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 3, Authorised, Last updated: 10/05/2023
List item

Human medicine European public assessment report (EPAR): Padcev (updated)

Enfortumab vedotin, Carcinoma, Transitional Cell; Urologic Neoplasms
Date of authorisation: 13/04/2022, , Revision: 1, Authorised, Last updated: 08/05/2023
List item

Human medicine European public assessment report (EPAR): Blincyto (updated)

blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015, , , Revision: 17, Authorised, Last updated: 08/05/2023
List item

Human medicine European public assessment report (EPAR): Lojuxta (updated)

Lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013, , , Revision: 16, Authorised, Last updated: 08/05/2023
List item

Human medicine European public assessment report (EPAR): Luxturna (updated)

voretigene neparvovec, Leber Congenital Amaurosis; Retinitis Pigmentosa
Date of authorisation: 22/11/2018, , , Revision: 6, Authorised, Last updated: 04/05/2023
List item

Human medicine European public assessment report (EPAR): Calquence

Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020, , Revision: 5, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Rybelsus

semaglutide, Diabetes Mellitus, Type 2
Date of authorisation: 03/04/2020, , Revision: 5, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Ozempic

semaglutide, Diabetes Mellitus
Date of authorisation: 08/02/2018, , Revision: 10, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Xenpozyme

Olipudase alfa, Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Date of authorisation: 24/06/2022, , , Revision: 1, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Tegsedi

inotersen sodium, Amyloidosis
Date of authorisation: 06/07/2018, , , Revision: 14, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Ocaliva

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 16, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Zynlonta

loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022, , , Revision: 2, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Yselty

linzagolix choline, Leiomyoma
Date of authorisation: 14/06/2022, , Revision: 3, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Imfinzi

durvalumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/09/2018, , Revision: 16, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Zejula

Niraparib (tosilate monohydrate), Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Date of authorisation: 16/11/2017, , , Revision: 20, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Palynziq

Pegvaliase, Phenylketonurias
Date of authorisation: 03/05/2019, , , Revision: 7, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Kalydeco

ivacaftor, Cystic Fibrosis
Date of authorisation: 23/07/2012, , Revision: 35, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Beyfortus

nirsevimab,
Date of authorisation: 31/10/2022, , Revision: 2, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Ronapreve

casirivimab, imdevimab, COVID-19 virus infection
Date of authorisation: 12/11/2021, , Revision: 4, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): NexoBrid

proteolytic enzymes enriched in bromelain, Debridement
Date of authorisation: 18/12/2012, , Revision: 15, Authorised, Last updated: 26/04/2023